BI 10773 Placebo

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2Healthy

Phase 1

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

CompletedNCT01195675

Boehringer IngelheimHealthy

Start: 2010-08-31Updated: 2014-07-28

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

CompletedNCT01924767

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2007-07-31End: 2007-11-30Updated: 2014-07-04

Phase 2

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

CompletedNCT01011868

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2009-11-30Updated: 2014-09-30

Phase 3

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

CompletedNCT01778049

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2013-01-31End: 2015-03-31Updated: 2016-04-04

Related Papers

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

2013-04-2437 citations